GenVec appoints chief medical officer
Executive Summary
Thomas Davis named to the post of chief medical officer at GenVec. Davis was previously the head of the hematologic malignancies portfolio for the Cancer Therapeutics Evaluation Program at the National Cancer Institute. He will oversee clinical development of the company's gene-based product candidates. FDA placed GenVec's oncologic TNFerade on clinical hold last October after Phase II trial data revealed a potential increased risk of blood clots...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.